Bausch + Lomb Raises Guidance on Strong Q1, Margin Expansion
Event summary
- Bausch + Lomb reported first-quarter 2026 revenue of $1.244 billion, up 9% year-over-year.
- Pharmaceuticals segment revenue grew by 14%, driven by MIEBO (+33%) and XIIDRA (+30%).
- The company raised its full-year 2026 revenue guidance from $5.375B - $5.475B to $5.420B - $5.520B.
- Operating income improved significantly to $33 million, compared to an $83 million operating loss in Q1 2025.
The big picture
Bausch + Lomb's strong Q1 results and revised guidance signal a successful turnaround strategy under Brent Saunders, demonstrating a focus on margin expansion and operational improvements. The company's reliance on acquisitions like MIEBO and XIIDRA highlights a growth-through-acquisition strategy common in the fragmented eye health market. The increased guidance suggests a more optimistic outlook for the broader eye care sector, though execution risks remain.
What we're watching
- Growth Sustainability
- Whether Bausch + Lomb can sustain the double-digit growth in its Pharmaceuticals segment, particularly given the reliance on MIEBO and XIIDRA, will be a key indicator of long-term performance.
- AI Integration
- The effectiveness of Bausch + Lomb's broad AI adoption in driving operational efficiencies and offsetting inflationary pressures warrants close monitoring.
- Regulatory Landscape
- The pace at which LUMIFY NXT and seeLYRA gain market share following regulatory approvals will influence the company’s ability to meet revised guidance.
Related topics